BrainStorm Has Secured a Second Manufacturing Facility for NurOwn, an Experimental Drug for ALS
BrainStorm Cell Therapeutics Inc. has announced that it has secured its second U.S. manufacturing location for NurOwn®, an experimental drug currently under investigation for the treatment of amyotrophic lateral sclerosis…